Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria
Open Access
- 14 January 2003
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 55 (1) , 6-13
- https://doi.org/10.1046/j.1365-2125.2003.01717.x
Abstract
Large oral doses of betaine have proved effective in lowering plasma homocysteine in severe hyperhomocysteinaemia. The pharmacokinetic characteristics and metabolism of betaine in humans have not been assessed and drug monitoring for betaine therapy is not available. We studied the pharmacokinetics of betaine and its metabolite dimethylglycine (DMG) in healthy subjects and in three patients with homocystinuria. Twelve male volunteers underwent an open-label study. After one single administration of 50 mg betaine kg-1 body weight and during continuous intake of twice daily 50 mg kg-1 body weight, serial blood samples and 24 h urines were collected to determine betaine and DMG plasma concentrations and urinary excretion, respectively. Patients were evaluated after one single dose of betaine. We found rapid absorption (t(1/2),abs 00.28 h, s.d. 0.17) and distribution (t(1/2), lambda1 00.59 h, s.d. 0.22) of betaine. A Cmax of 0.94 mmol l-1 (s.d. 0.19) was reached after tmax 00.90 h (s.d. 0.33). The elimination half life t(1/2), z was 14.38 h (s.d. 7.17). After repeated dosage, t(1/2), lambda1 (01.77 h, s.d. 0.75) and t(1/2), z (41.17 h, s.d. 13.50) increased significantly (95% CI 0.73, 01.64 h and 19.90, 33.70 h, respectively), whereas absorption remained unchanged. DMG concentrations increased significantly after betaine administration and accumulation occurred to the same extent as with betaine. Renal clearance was low and urinary excretion of betaine was equivalent to 4% of the ingested dose. Distribution and elimination kinetics in homocystinuric patients appeared to be accelerated. Betaine plasma concentrations change rapidly after ingestion. Elimination half-life increased during continuous dosing over 5 days. Betaine is mainly eliminated by metabolism. More pharmacokinetic and pharmacodynamic studies in hyperhomocysteinaemic patients are needed to refine the current treatment with betaine.Keywords
This publication has 24 references indexed in Scilit:
- Polymorphisms in the Methylenetetrahydrofolate Reductase GeneAmerican Journal of PharmacoGenomics, 2001
- Evidence for mitochondrial localization of betaine aldehyde dehydrogenase in rat liver: purification, characterization, and comparison with human cytoplasmic E3 isozymeBiochemistry and Cell Biology, 1999
- Human Betaine–Homocysteine Methyltransferase Is a Zinc MetalloenzymeArchives of Biochemistry and Biophysics, 1998
- Glycine betaine and proline betaine in human blood and urineBiochimica et Biophysica Acta (BBA) - General Subjects, 1994
- Choline and Human NutritionAnnual Review of Nutrition, 1994
- Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolismMetabolism, 1993
- Organic osmolytes in human and other mammalian kidneysKidney International, 1993
- Molecular cloning of a plant betaine-aldehyde dehydrogenase, an enzyme implicated in adaptation to salinity and drought.Proceedings of the National Academy of Sciences, 1990
- Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiencyEuropean Journal of Pediatrics, 1984
- Results of betaine treatment of AtherosclerosisDigestive Diseases and Sciences, 1952